Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.

Trial Profile

Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2012

At a glance

  • Drugs Belinostat; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Mar 2012 Actual patient number (7) added as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Planned end date changed from 1 Jan 2013 to 1 Feb 2012 as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top